AT
Avenue Therapeutics, Inc.
ATXI · OTC
$0.48 -15.30% (-$0.09)
1M +19.39%
Market Cap $1.57M
P/E Ratio -
Div. Yield -
ROE 155.23%
Bulios Fair Price
$0.67
40.3% upside
Current Price
$0.48
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ATXI is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
71 /100
Cheap P/B 2.77x
EV/EBITDA N/A
P/S N/A
Growth
0 /100
Declining Book val. growth 22.30%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 155.23%
ROA 140.54%
Asset turnover 0.00x
Debt
88 /100
Low Current ratio 1.38x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
34 /100
Moderate EPS volatility 51.26%
Profitable years 0
Beta -0.17x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ATXI
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Alexandra MacLean
Employees
1
Headquarters
Bay Harbor Islands
Upcoming events
13 NOV
Earnings
Upcoming earnings report